These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17360784)

  • 1. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases.
    Huvers FC; Popa C; Netea MG; van den Hoogen FH; Tack CJ
    Ann Rheum Dis; 2007 Apr; 66(4):558-9. PubMed ID: 17360784
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy.
    Rosenvinge A; Krogh-Madsen R; Baslund B; Pedersen BK
    Scand J Rheumatol; 2007; 36(2):91-6. PubMed ID: 17476613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Vasakos S; Nikas SN; Drosos AA
    Ann Rheum Dis; 2005 May; 64(5):765-6. PubMed ID: 15458960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumour necrosis factor agents and lipid profile: a class effect?
    Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
    Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
    [No Abstract]   [Full Text] [Related]  

  • 5. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
    Smith JR; Levinson RD; Holland GN; Jabs DA; Robinson MR; Whitcup SM; Rosenbaum JT
    Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab and insulin resistance.
    Ursini F; Naty S; Grembiale RD
    Autoimmun Rev; 2010 Jun; 9(8):536-9. PubMed ID: 20060507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
    Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
    J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity.
    Seriolo B; Ferrone C; Cutolo M
    J Rheumatol; 2008 Feb; 35(2):355-7. PubMed ID: 18260166
    [No Abstract]   [Full Text] [Related]  

  • 9. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
    Yelin E; Katz P
    Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
    [No Abstract]   [Full Text] [Related]  

  • 10. Rheumatoid vasculitis treated with infliximab.
    van der Bijl AE; Allaart CF; Van Vugt J; Van Duinen S; Breedveld FC
    J Rheumatol; 2005 Aug; 32(8):1607-9. PubMed ID: 16078342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment.
    Briot K; Garnero P; Le Henanff A; Dougados M; Roux C
    Ann Rheum Dis; 2005 Aug; 64(8):1137-40. PubMed ID: 15642695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection and anti-tumor necrosis factor-alpha therapy.
    Zandman-Goddard G
    Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
    [No Abstract]   [Full Text] [Related]  

  • 14. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biological treatment of rheumatic diseases].
    Procházková L; Böhmová J; Soucek M
    Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
    Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
    J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density in patients with rheumatoid arthritis treated with infliximab.
    Vis M; Voskuyl AE; Wolbink GJ; Dijkmans BA; Lems WF;
    Ann Rheum Dis; 2005 Feb; 64(2):336-7. PubMed ID: 15647447
    [No Abstract]   [Full Text] [Related]  

  • 18. Should tuberculin skin test be positive to give latent tuberculosis treatment before tumor necrosis factor-alpha inhibitors in selected patients in developing countries?
    Abud-Mendoza C; Martínez-Martínez MU; DE Jesús Macías-Mendoza J; Magaña-Aquino M
    J Rheumatol; 2010 Mar; 37(3):672-3; author reply 673. PubMed ID: 20197567
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-cytokine antibodies for rheumatic diseases.
    Atzeni F; Sarzi-Puttini P
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three years experience with the prescription of anti-TNF-alpha inhibitors at Dr Soliman Fakeeh Hospital in Jeddah, Saudi Arabia.
    Eleishi HH; Toma NF; Chaki MC; Nada HR
    Int J Rheum Dis; 2009 Apr; 12(1):14-9. PubMed ID: 20374311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.